Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2019

View Archived Issues

Murine model reveals TRPA1 loss is involved in age-related dilated cardiomyopathy

Molecular Partners initiates first-in-human study of MP-0310

Tiziana presents phase I results for nasal foralumab

Positive CTC data from phase II TYME-88-PANC study of SM-88

ANKRD12 as a novel biomarker in schizophrenia and bipolar disorder

S100-B found to be a peripheral biomarker for estimating addiction treatment efficacy

NEK7 identified as potential biomarker associated with obsessive compulsive disorder

Transgenic CYP2C19 mouse as a new animal model for hyperdopaminergism-induced hyperkinesia

Gilead discloses new HIV replication inhibitors

Incyte presents new MAP4K1 inhibitors

New analgesics synthesized at Daiichi Sankyo

Memorial Sloan-Kettering Cancer Center patents anticancer agents

Girafpharma describes cyclin-dependent kinase inhibitors

KAHR Medical, Roche trial collaboration to test DSP-107/atezolizumab in lung cancer

Phio Pharmaceuticals enters agreement with Carisma Therapeutics to enhance adoptive cell therapy

P53 upregulation predicts malaria immunity in children

FDA approves Xeris' Gvoke, first ready-to-use stable liquid glucagon for severe hypoglycemia

Oryzon Genomics presents preliminary phase II data on iadademstat in SCLC

Glioblastoma stem cells co-opt circadian pacemakers

Ocrelizumab in RRMS: CASTING study phase III results presented

Tubulis enters collaboration with Glycotope for development of novel ADC therapy

Adverum reports 24-week cohort 1 data from phase I study of ADVM-022 in wet AMD

Prevail Therapeutics advances development of PR-001 for Parkinson's and Gaucher's diseases

Moderna offers phase I data from chikungunya and CMV programs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...